trending Market Intelligence /marketintelligence/en/news-insights/trending/cH6fqI1466mufoWU8quItQ2 content esgSubNav
In This List

MacroGenics seeks US FDA approval for breast cancer drug

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


MacroGenics seeks US FDA approval for breast cancer drug

Rockville, Md.-based MacroGenics Inc. filed an application with the U.S. Food and Drug Administration for approval of margetuximab to treat certain breast cancer patients.

SNL Image

The company's biologics license application of margetuximab is for treating previously treated patients with HER2-positive breast cancer whose cancer has spread to other organs of the body, in combination with chemotherapy.

The application is supported by data from a late-stage study, dubbed Sophia, which showed that patients receiving the combination experienced a slower progression of the disease compared to Roche Holding AG's Herceptin, or trastuzumab. The combination was also better in shrinking the size of the tumors.

Margetuximab is an investigational monoclonal antibody, designed to block HER2, which can propagate the growth of cancer cells, and enhance the engagement of the immune system.